Table 5.
Treatment-related information for the CCU admission cohort.
Staffing model | Clinical | Integrated | Total | Test | p | |
---|---|---|---|---|---|---|
Site 1 (n = 53) |
Site 2 (n = 52) |
Site 3 (n = 40) |
(N = 145) | |||
Referral and Legal status | ||||||
Community-based referrala | 56.6% | 63.5% | 62.5% | 60.7% | X2 (2) = .593 | .743 |
Involuntary treatmentb | 52.8% | 51.9% | 32.5% | 46.9% | X2 (2) = .4.606 | .102 |
Guardianship order present | 5.7% | 3.8% | 5.0% | 4.8% | Fisher’s Exact Testc | 1.000 |
Medications prescribed | ||||||
Anti-psychotic medication: | ||||||
- CPZ equivalent dose (, mg) | 436.2 (365.3) | 436.4 (284.5) | 361.3 (257.7) | 415.6 (309.8) | K(2) = 2.073 | .355 |
- Depot prescribed | 45.3% | 50.0% | 40.0% | 45.5% | X2 (2) = 0.914 | .633 |
- Clozapine prescribed | 17.0% | 25.0% | 37.5% | 25.5% | X2 (2) = 5.061 | .080 |
- Number of antipsychotics | 1.36 (0.71) | 1.42 (0.696) | 1.15 (0.58) | 1.32 (0.676) | K(2) = 4.528 | .104 |
Mood stabiliser: | ||||||
- Lithium | 20.8% | 21.2% | 10.0% | 17.9% | X2 (2) = 2.364 | .307 |
- Sodium valproate | 9.4% | 15.4% | 12.5% | 12.4% | X2 (2) = .855 | .652 |
- Other | 7.5% | 3.8% | 0.0% | 4.1% | X2 (2) = 3.291 | .193 |
Other medication: | ||||||
- Antidepressant | 41.5% | 44.2% | 42.5% | 42.8% | X2 (2) = .081 | .960 |
- Benzodiazepine(s) | 13.2% | 17.3% | 7.5% | 13.1% | X2 (2) = 1.911 | .385 |
Community-based referral compared to combined acute (35.2%) and sub-acute (4.1%) inpatient referral source.
Involuntary treatment includes both Involuntary Treatment Orders (43.5%) and Forensic Orders (3.4%).
Unadjusted odds ratio: Guardianship order present = .359.